Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Authors Woods A, Wheeler J, Finch C, Pinner N

Received 14 January 2014

Accepted for publication 6 March 2014

Published 3 May 2014 Volume 2014:9(1) Pages 421—430

DOI https://doi.org/10.2147/COPD.S51012

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

J Andrew Woods,1 James S Wheeler,1 Christopher K Finch,2 Nathan A Pinner3

1School of Pharmacy, Wingate University, Wingate, NC, USA; 2Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA; 3Harrison School of Pharmacy, Auburn University, Auburn, AL, USA

Background: Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease that affects an estimated 10% of the world's population over the age of 40 years. Worldwide, COPD ranks in the top ten for causes of disability and death. Given the significant impact of this disease, it is important to note that acute exacerbations of COPD (AECOPD) are by far the most costly and devastating aspect of disease management. Systemic steroids have long been a standard for the treatment of AECOPD; however, the optimal strategy for dosing and administration of these medications continues to be debated.
Objective: To review the use of corticosteroids in the treatment of acute exacerbations of COPD.
Materials and methods: Literature was identified through PubMed Medline (1950–February 2014) and Embase (1950–February 2014) utilizing the search terms corticosteroids, COPD, chronic bronchitis, emphysema, and exacerbation. All reference citations from identified publications were reviewed for possible inclusion. All identified randomized, placebo-controlled trials, meta-analyses, and systematic reviews evaluating the efficacy of systemic corticosteroids in the treatment of AECOPD were reviewed and summarized.
Results: The administration of corticosteroids in the treatment of AECOPD was assessed. In comparison to placebo, systemic corticosteroids improve airflow, decrease the rate of treatment failure and risk of relapse, and may improve symptoms and decrease the length of hospital stay. Therefore, corticosteroids are recommended by all major guidelines in the treatment of AECOPD. Existing literature suggests that low-dose oral corticosteroids are as efficacious as high-dose, intravenous corticosteroid regimens, while minimizing adverse effects. Recent data suggest that shorter durations of corticosteroid therapy are as efficacious as the traditional treatment durations currently recommended by guidelines.
Conclusion: Systemic corticosteroids are efficacious in the treatment of AECOPD and considered a standard of care for patients experiencing an AECOPD. Therefore, systemic corticosteroids should be administered to all patients experiencing AECOPD severe enough to seek emergent medical care. The lowest effective dose and shortest duration of therapy should be considered.

Keywords: chronic obstructive pulmonary disease, exacerbation


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility

Samuel SP, Santos-Martinez MJ, Medina C, Jain N, Radomski MW, Prina-Mello A, Volkov Y

International Journal of Nanomedicine 2015, 10:2723-2734

Published Date: 2 April 2015

Continuing to Confront COPD International Surveys: comparison of patient and physician perceptions about COPD risk and management

Menezes AM, Landis SH, Han MK, Muellerova H, Aisanov Z, van der Molen T, Oh YM, Ichinose M, Mannino DM, Davis KJ

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:159-172

Published Date: 20 January 2015

Central airways remodeling in COPD patients

Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:927-933

Published Date: 1 September 2014

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:715-721

Published Date: 9 July 2014

Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease

Wang XR, Li YP, Gao S, Xia W, Gao K, Kong QH, Qi H, Wu L, Zhang J, Qu JM, Bai CX

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:543-549

Published Date: 27 May 2014

Cytokine inhibition in the treatment of COPD

Caramori G, Adcock IM, Di Stefano A, Chung KF

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:397-412

Published Date: 28 April 2014

Clinical issues of mucus accumulation in COPD

Osadnik CR, McDonald CF, Holland AE

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:301-302

Published Date: 25 March 2014